Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
MXCT MaxCyte
6.660
-0.630-8.64%
Post Mkt Price
6.6600.0000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Assets
Current assets
Cash, cash equivalents and short term investments
228.22% 240.89M -- 246.28M 633.67% 255.04M 633.67% 255.04M
-Cash and cash equivalents
191.71% 109.17M -- 239.78M 154.77% 47.78M 154.77% 47.78M
-Short-term investments
266.21% 131.72M -- 6.5M 1194.78% 207.26M 1194.78% 207.26M
Receivables
38.28% 7.91M -- 10.75M 32.97% 6.88M -- 6.88M
-Accounts receivable
38.28% 7.91M -- 10.75M 32.97% 6.88M 32.97% 6.88M
Inventory
85.2% 7.72M -- 6.58M 20.59% 5.2M 20.59% 5.2M
Prepaid assets
-- 1.31M -- 2.19M -- 3.31M -- 3.31M
Total current assets
204.67% 257.83M -- 265.79M 497.6% 270.43M 497.6% 270.43M
Non current assets
Net PPE
355.15% 31.03M -- 24.11M 105.93% 13.37M 105.93% 13.37M
-Gross PPE
355.15% 31.03M -- 28.95M 87.39% 17.74M 41.21% 13.37M
-Accumulated depreciation
-- -- -- -4.85M -46.94% -4.37M -- --
Other non current assets
-45.98% 920.5K -- 1.05M 834.22% 316.7K 834.22% 316.7K
Total non current assets
274.92% 31.95M -- 25.16M 109.71% 13.69M 109.71% 13.69M
Total assets
211.1% 289.78M -- 290.96M 448.71% 284.12M 448.71% 284.12M
Liabilities
Current liabilities
Payables
281% 2.46M -- 4.37M 104.48% 1.82M 104.48% 1.82M
-accounts payable
281% 2.46M -- 4.37M 104.48% 1.82M 104.48% 1.82M
Current accrued expenses
74.88% 7.9M -- 3.87M 25.25% 6.52M -- 6.52M
Current debt and capital lease obligation
-28.84% 438.7K -- 480.2K -21.62% 527.2K -21.62% 527.2K
-Current capital lease obligation
-28.84% 438.7K -- 480.2K -21.62% 527.2K -21.62% 527.2K
Current deferred liabilities
8.23% 7.31M -- 6.83M 39.31% 6.75M -- 6.75M
Current liabilities
44.46% 18.11M -- 15.55M 34.47% 15.62M 34.47% 15.62M
Non current liabilities
Long term debt and capital lease obligation
2216.35% 14.05M -- 12.77M -18.1% 5.15M -18.1% 5.15M
-Long term capital lease obligation
2216.35% 14.05M -- 12.77M 274.41% 5.15M 274.41% 5.15M
Other non current liabilities
-66.84% 393K -- 451.1K -30.37% 450.2K -30.37% 450.2K
Total non current liabilities
706.29% 14.45M -- 13.22M -19.24% 5.61M -19.24% 5.61M
Total liabilities
127.24% 32.55M -- 28.77M 14.38% 21.22M 14.38% 21.22M
Shareholders'equity
Share capital
20% 1.02M -- 1.02M 30.78% 1.01M 30.78% 1.01M
-common stock
20% 1.02M -- 1.02M 30.78% 1.01M 30.78% 1.01M
-Preferred stock
-- 0 -- 0 -- 0 -- --
Retained earnings
-18.63% -126.63M -- -118.37M -20.04% -114.3M -20.04% -114.3M
Paid-in capital
107.25% 382.84M -- 379.54M 194.65% 376.19M 194.65% 376.19M
Total stockholders'equity
226.34% 257.22M -- 262.18M 691.25% 262.9M 691.25% 262.9M
Total equity
226.34% 257.22M -- 262.18M 691.25% 262.9M 691.25% 262.9M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.
CEO: Mr. Douglas Arthur Doerfler
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...